Please use this identifier to cite or link to this item:
http://sgc.anlis.gob.ar/handle/123456789/67
Title: | Ensayo preclínico de la vacuna candid #1 producida en Argentina contra la fiebre hemorrágica Argentina | Authors: | Ambrosio, Ana M. Riera, Laura Saavedra, María del Carmen Sottosanti, María J. |
Keywords: | Fiebre Hemorrágica Americana;Vacunas Virales;Vacunas Atenuadas;Virus Junin;Estudios de Casos y Controles;Modelos Animales de Enfermedad;Argentina | Issue Date: | 2005 | Description: | Se comparó en cobayos la seguridad, inmunogenicidad y eficacia protectora de un lote de vacuna Candid #1(C#1) fabricada en Estados Unidos de América (EE.UU.) y distintos lotes de la misma vacuna fabricados en Argentina (Arg). El lote TSI 5-1-92 (EE.UU.) y los lotes Exp Nº 3, 7A y 8A (Arg) fueron inoculados (0.5 ml, IM) en cobayos de 250-400 g. Para cada ensayo diez animales recibieron solución fisiológica y sirvieron como control. Todos fueron desafiados con la cepa patógena P23790 de virus Junin. Se registró: a) temperatura rectal, b) peso corporal, c) presencia de anticuerpos neutralizantes (AcNT) pre y post-vacunación, d) respuesta al desafío. Todos los animales vacunados desarrollaron AcNT anti virus Junin (rango = 40- 81920 y sobrevivieron al desafío. En cada grupo control 8/10 animales murieron (día 23.3 ± 5.4 post-desafío). Los cobayos resultaron idénticamente protegidos de una descarga letal de virus Junin por la vacuna importada y los diferentes lotes de C#1 producidos en Argentina. Preclinical assay of Candid #1 vaccine against Argentine Hemorrhagic Fever made in Argentina. Candid #1 vaccine against Argentine Hemorrhagic Fever produced in USA versus lots of the same vaccine made in Argentina were compared in guinea pigs regarding safety, immunogenicity and protective efficacy against a challenge with pathogenic Junin virus. Lots Nº Exp 3, 7A and 8A of Argentine origin as well as lot TSI 5-1-92 from USA were inoculated in guinea pigs of 250-400 g in two consecutive assays. Ten animals inoculated with saline performed as normal controls in each experiment. Parameters studied were: a) temperature; b) body weight; c) neutralizing antibodies to Junin virus; d) response to viral challenge. Animals gained weight and remained normothermic up to the challenge. Guinea pigs that received Candid #1 from any manufacturer elicited neutralizing antibodies to Junin virus (titles from 40 to 81920) and survived to challenge whilst 8/10 animals died in each control group. Data presented demonstrated that Candid #1 vaccines from USA or Argentine manufacturers were equally safe, immunogenic and protective in guinea pigs. Fil: Ambrosio, Ana M. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas Dr. Julio Maiztegui; Argentina. Fil: Saavedra, María del Carmen. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas Dr. Julio Maiztegui; Argentina. Fil: Riera, Laura M. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas Dr. Julio Maiztegui; Argentina. Fil: Sottosanti, María J. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Virales Humanas Dr. Julio Maiztegui; Argentina. |
URI: | http://sgc.anlis.gob.ar/handle/123456789/67 http://www.scielo.org.ar/pdf/medba/v65n4/v65n4a08.pdf |
ISSN: | 0025-7680 | Rights: | info:eu-repo/semantics/openAccess |
Appears in Collections: | snrd Publicaciones INEVH |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Medicina (Buenos Aires), 2005, 65(4), 329–332..pdf | 93.02 kB | Adobe PDF | View/Open |
Page view(s)
83
checked on Oct 30, 2024
Download(s)
14
checked on Oct 30, 2024
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.